Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Trevi Therapeutics Inc (TRVI)
NASDAQ:TRVI
Holding TRVI?
Track your performance easily
TRVI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.00 - $4.00
Previous Close$2.88
Volume93.61K
Average Volume (3M)483.89K
Market Cap
$221.37M
Enterprise Value$156.99M
Total Cash (Recent Filing)$65.49M
Total Debt (Recent Filing)$1.11M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Mar 19, 2025EPS Estimate
-$0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding76,865,711
10 Day Avg. Volume700,280
30 Day Avg. Volume483,895
Standard Deviation0.44
R-Squared0.01
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)3.60
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-6.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.59
Forecast
1Y Price Target
$9.13Price Target Upside217.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Trevi Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe RIVER study is being over-enrolled to demonstrate efficacy across all refractory chronic cough subtypes, suggesting a commitment to comprehensive results.
Market PotentialHaduvio's evaluation in refractory chronic cough could significantly expand its total addressable market, setting it apart from competitors with lackluster efficacy.
Stock ValuationMultiple catalysts are expected by early 2025 to reset the TRVI equity value floor to a higher level, providing opportunities for growth.
Bears Say
Clinical TrialsAny delays or unfavorable outcome from the ongoing or planned clinical trials of Haduvio could significantly affect the company’s valuation.
Company ExperienceTrevi has never commercialized a drug product on its own, so projected future sales of Haduvio may not materialize due to lack of experience and/or expertise.
Therapeutic EfficacyP2X3 assets leave much to be desired, with Merck’s gefapixant rejected by the FDA citing insufficient efficacy.
---
Ownership Overview
12.63% Insiders
6.42% Mutual Funds
60.82% Other Institutional Investors
12.89% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TRVI FAQ
What was Trevi Therapeutics Inc’s price range in the past 12 months?
Trevi Therapeutics Inc lowest stock price was $1.00 and its highest was $4.00 in the past 12 months.
What is Trevi Therapeutics Inc’s market cap?
Currently, no data Available
When is Trevi Therapeutics Inc’s upcoming earnings report date?
Trevi Therapeutics Inc’s upcoming earnings report date is Mar 19, 2025 which is in 87 days.
How were Trevi Therapeutics Inc’s earnings last quarter?
Trevi Therapeutics Inc released its earnings results on Nov 06, 2024. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of -$0.12 by -$0.01.
Is Trevi Therapeutics Inc overvalued?
According to Wall Street analysts Trevi Therapeutics Inc’s price is currently Undervalued.
Does Trevi Therapeutics Inc pay dividends?
Trevi Therapeutics Inc does not currently pay dividends.
What is Trevi Therapeutics Inc’s EPS estimate?
Trevi Therapeutics Inc’s EPS estimate is -$0.12.
How many shares outstanding does Trevi Therapeutics Inc have?
Trevi Therapeutics Inc has 76,865,710 shares outstanding.
What happened to Trevi Therapeutics Inc’s price movement after its last earnings report?
Trevi Therapeutics Inc reported an EPS of -$0.13 in its last earnings report, missing expectations of -$0.12. Following the earnings report the stock price went down -6.452%.
Which hedge fund is a major shareholder of Trevi Therapeutics Inc?
Among the largest hedge funds holding Trevi Therapeutics Inc’s share is Viking Global Investors LP. It holds Trevi Therapeutics Inc’s shares valued at 15M.
---
Trevi Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.13 (217.01% Upside)
$9.13 (217.01% Upside)
Blogger Sentiment
Bullish
TRVI Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 606.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $188.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days >0.1%
Last 30 Days ▲ 43.2%
Last 30 Days ▲ 43.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
164.22%
12-Months-Change
Fundamentals
Return on Equity
-59.65%
Trailing 12-Months
Asset Growth
-28.14%
Trailing 12-Months
Company Description
Trevi Therapeutics Inc
Trevi Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good on March 17, 2011 and is headquartered in New Haven, CT.
---
TRVI Earnings Call
Q3 2024
0:00 / 0:00
---
TRVI Stock 12 Month Forecast
Average Price Target
$9.13
▲(217.01% Upside)
Technical Analysis
KalVista Pharmaceuticals
―
EyePoint Pharmaceuticals
―
Aldeyra Therapeutics
―
Xeris Pharmaceuticals
―
Best Analysts Covering TRVI
1 Year
1 Year Success Rate
4/8 ratings generated profit
1 Year Average Return
+23.18%
reiterated a buy rating 3 months ago
Copying Leland Gershell's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +23.18% per trade.
---